Navigation Links
NKTR-102 Demonstrates Significant Efficacy as Single-Agent in Second- or Third-Line Treatment in Metastatic Breast Cancer Patients
Date:12/12/2010

company partners, including UCB's Cimzia(R) for Crohn's disease and rheumatoid arthritis, Roche's PEGASYS(R) for hepatitis C and Amgen's Neulasta(R) for neutropenia.

Nektar has created a robust pipeline of potentially high-value therapeutics to address unmet medical needs by leveraging and expanding its technology platforms to improve and enable molecules.  In addition to the releasable polymer technology, Nektar is the first company to create a permanent small molecule-polymer conjugate with enhanced oral bioavailability and restricted entry into the CNS.  Nektar is currently conducting clinical and preclinical programs in oncology, pain and other therapeutic areas.  Nektar recently entered into an exclusive worldwide license agreement with AstraZeneca for its oral NKTR-118 program to treat opioid-induced constipation and its NKTR-119 program for the treatment of pain without constipation side effects.  NKTR-102 is being evaluated in Phase 2 clinical studies for the treatment of ovarian, breast and colorectal cancers.  NKTR-105 is in a Phase 1 clinical study in cancer patients with refractory solid tumors.

Nektar is headquartered in San Francisco, California, with additional R&D operations in Huntsville, Alabama and Hyderabad, India.  Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com.

This press release contains forward-looking statements that reflect Nektar's current views regarding the potential of Nektar's technology platform, the potential of NKTR-102 for breast cancer patients, and preliminary results from the Phase 2 clinical trial of NKTR-102 in metastatic breast cancer.  These forward-looking statements involve substantial risks and uncertainties, including but not limited to one or more of the following: (i) NKTR-102 is in mid-stage clinical development and the risk of failur
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. NKTR-102 Shows Encouraging Anti-Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplinary Congress
2. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
3. Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
4. Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings
5. Additive Anti-Tumor Activity of NKTR-102 in Combination With Bevacizumab Highlighted in Positive Preclinical Data Presented at AACR Meeting
6. Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
7. NKTR-102 (PEG-Irinotecan) Demonstrates Significant Tumor Growth Inhibition In Multiple Preclinical Tumor Models
8. Tumor Growth Inhibition and Pharmacokinetic Profile of NKTR-102 (PEG-Irinotecan) in Multiple Solid Tumors To Be Presented at Upcoming AACR-NCI-EORTC International Conference
9. Phase 2 Data Presented at the 52nd Annual Meeting of the American Society of Hematology Demonstrates Promising Efficacy of KRX-0401 (Perifosine) in the Treatment of Advanced Leukemia, Lymphoma and Multiple Myeloma
10. Halozymes rHuPH20 With Recombinant Human Insulin Demonstrates Glycemic Control Comparable to Lispro
11. Pevions Breakthrough Candida Vaccine Demonstrates Safety and Immunogenicity in Phase I Clinical Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... NEW YORK and KISSING, Germany ... manufacturer and distributor of a single use and computer-assisted ... Nachum (Homi) Shamir , a worldwide recognized medical device ... Mr. Shamir is a highly respected ... most recent assignment he served as President and Chief ...
(Date:7/30/2014)... PARIS , July 30, 2014  Regeneron Pharmaceuticals, ... SAN and NYSE: SNY ) today announced ... in people with hypercholesterolemia met their primary efficacy endpoint ... lipoprotein cholesterol (LDL-C) at 24 weeks compared to placebo ... targeting PCSK9 (proprotein convertase subtilisin/kexin type 9). ...
(Date:7/30/2014)... July 30, 2014  DigiPath, Inc. (OTCBB and OTCQB: ... into the cannabis testing and education markets, announced today ... and affairs not previously disclosed or, to its knowledge, ... market action. "We have noticed unusual price ... three trading days," said Steve Barbee , CEO ...
Breaking Medicine Technology:invendo medical Appoints Nachum (Homi) Shamir To The Company's Board Of Directors 2invendo medical Appoints Nachum (Homi) Shamir To The Company's Board Of Directors 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 2Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 4Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 5Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 6Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 7Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 8DigiPath No New Corporate Developments 2
... , SAN FRANCISCO, Nov. 4 VIA Pharmaceuticals, Inc. ... the development of compounds for the treatment of cardiovascular ... Senior Vice President Research & Development will present "VIA-3196, ... in the Abstract Oral Session on Novel Biological Mechanisms ...
... CVS Caremark (NYSE: CVS ) today announced ... SVP, Marketing for its pharmacy benefit management business. ... Jack Bruner, who is transitioning to the new role ... http://www.newscom.com/cgi-bin/prnh/20090226/NE75914LOGO ) , Greer brings twenty years ...
Cached Medicine Technology:VIA Pharmaceuticals Featured at American Heart Association Scientific Sessions 2009 2VIA Pharmaceuticals Featured at American Heart Association Scientific Sessions 2009 3VIA Pharmaceuticals Featured at American Heart Association Scientific Sessions 2009 4Company Appoints New SVP, Marketing for PBM Business 2
(Date:7/30/2014)... Victory Medical Center Craig Ranch , ... launch of a pediatric unit focused on: orthopedics, ear, ... working in the pediatrics departments are all specially trained ... Dr. Timothy Cole, Dr. Dale Ehmer, Dr. Barry Humeniuk, ... and Dr. Nicholas Peiffer lead the pediatrics team. Victory ...
(Date:7/30/2014)... Building ENT and Allergy Associates (ENTA) into the ... Westchester County takes the best of everything. Leading physicians, ... structure and protocols, and a staff that is second ... Financial Officer to help run it. According to the ... possesses. In fact, in the WCBJ’s July 21st, 2014 ...
(Date:7/30/2014)... TUESDAY, July 29, 2014 (HealthDay News) -- A simple ... as spina bifida, new research finds. The test ... B) in a pregnant women,s red blood cells. The findings ... scientists -- could help doctors predict the risk of serious ... vital to the proper development of a growing fetus. ...
(Date:7/30/2014)... Tallahassee, FL (PRWEB) July 30, 2014 ... engineering doctoral candidate Renee Gordon and biochemistry professor ... August to conduct research as Fulbright Scholars. The ... international education exchange program that awards grants to ... teach and conduct research abroad. Both Gordon and ...
(Date:7/30/2014)... As a leading outpatient surgery clinic ... boasts over 50 of the best physicians across fourteen ... Health Systems’ team are Dr. Benjamin Basseri and Dr. ... , Benjamin Basseri, MD, is a board-certified gastroenterologist. He ... followed by a fellowship in Gastroenterology at UCLA Medical ...
Breaking Medicine News(10 mins):Health News:Victory Medical Center Craig Ranch Debuts Pediatric Care Unit 2Health News:Victory Medical Center Craig Ranch Debuts Pediatric Care Unit 3Health News:The Leading Ear, Nose, and Throat Practice in Westchester County Has One of the Leading CFO’s in Westchester County! 2Health News:The Leading Ear, Nose, and Throat Practice in Westchester County Has One of the Leading CFO’s in Westchester County! 3Health News:Blood Test Might Help Prevent Certain Birth Defects 2Health News:FAMU Professor and Engineering Student Named Fulbright Scholars 2Health News:FAMU Professor and Engineering Student Named Fulbright Scholars 3Health News:La Peer Welcomes Two New Gastroenterologists 2Health News:La Peer Welcomes Two New Gastroenterologists 3
... (Nasdaq: SIAL ) is pleased to announce ... Corporate Controller effective April 13, 2009. Kanan (age 46) ... President-Strategy & Corporate Development. He will report to ... brings two decades of financial experience in assignments of ...
... Reovirus seeks out and destroys tumor cells, researchers say ... harmless human virus can target and kill breast cancer ... reovirus might be effective against cancer stem cells, because ... destroys regular cancer cells," Dr. Patrick Lee, a cancer ...
... Tau has been promoted to the position of Service ... at Baron Center, Inc (BCI). Dr. Tau is ... & forensic psychology. Dr. Tau is an expert in ... and has been extensively used as a workplace violence ...
... at Johns Hopkins have begun to tease out what there ... that leads so many patients to report depression after they ... 10 in Critical Care Medicine , the Hopkins researchers ... hospitalization among very sick ICU patients, including a high level ...
... dopamine agonists appear to curb compulsive acting out, study ... class of Parkinson,s disease drugs called dopamine agonists can ... gambling or hypersexuality, says a new study. , ... taking therapeutic doses of dopamine agonists, such as pramipexole ...
... Sinai faculty suggests that a gene associated with onset ... cases. The research, led by Dr. Giulio Maria Pasinetti, ... Professor of Psychiatry and Geriatrics and Adult Development at ... in the scientific journal, Archives of Neurology . ...
Cached Medicine News:Health News:Sigma-Aldrich Announces Appointment of Michael Kanan as Vice President and Corporate Controller 2Health News:Harmless Virus May Be Deadly to Breast Cancer 2Health News:Manny Tau, Psy.D. Promoted to Service Area Leader for the Problematic Behaviors Service Area at Baron Center, Inc 2Health News:In the ICU, use of benzodiazepines, other factors may predict severity of post-stay depression 2Health News:Parkinson's Drugs Can Trigger Unhealthy Behaviors 2Health News:Mount Sinai researchers discover novel mechanisms that might causally link type-2 diabetes to Alzheimer's disease 2
Inquire...
Sealing Mat for 384-well, Square Well Plates Available Sterile...
96-well Silicone Expansion Mat, Bulk...
Microseal 'M' mats, seals 96-well plates, reusable, pkg of 10...
Medicine Products: